BridgeBio Pharma's (BBIO) acoramidis has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, which recommended granting a marketing authorization for the drug to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy, the regulator said Friday.
The CHMP cited a pivotal study that showed treatment with acoramidis, or Beyonttra, reduced cardiovascular hospitalizations over a 30-month period, according to the regulator.
BridgeBio said it expects a final decision from the European Commission "in the coming months" and plans to launch the drug in Europe in H1 2025.
Acoramidis was approved by the US Food and Drug Administration last month as Attruby, BridgeBio added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。